CDK4 and cancer: In this phase I/II study, abemaciclib will be given prior to Lu-PSMA-617 to evaluate if the CDK4/6 is able to upregulate prostate-specific membrane antigen (PSMA) expression in the cancer cells and, as such, potentiate the effects of Lu-PSMA-617.